Survival outcomes of patients with metastatic non-small cell lung cancer receiving chemotherapy or immunotherapy as first-line in a real-life setting
Treatment of metastatic non-small cell lung cancer (mNSCLC) has been modified due to the development of immunotherapy. We assessed survival outcomes (overall [OS] and progression-free [rwPFS] survivals, time-to-next-treatment [TNT]) in mNSCLC patients after first-line immunotherapy and chemotherapy...
Uloženo v:
| Vydáno v: | Scientific reports Ročník 13; číslo 1; s. 9584 - 11 |
|---|---|
| Hlavní autoři: | , , , , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
London
Nature Publishing Group UK
13.06.2023
Nature Publishing Group Nature Portfolio |
| Témata: | |
| ISSN: | 2045-2322, 2045-2322 |
| On-line přístup: | Získat plný text |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | Treatment of metastatic non-small cell lung cancer (mNSCLC) has been modified due to the development of immunotherapy. We assessed survival outcomes (overall [OS] and progression-free [rwPFS] survivals, time-to-next-treatment [TNT]) in mNSCLC patients after first-line immunotherapy and chemotherapy in real-life settings. Association between rwPFS and TNT, two candidate surrogate endpoints (SE), with OS was assessed. This retrospective multi-center study uses data from patients included in the Epidemio-Strategy Medico-Economic program with mNSCLC over 2015–2019. The impact of treatment on rwPFS/OS was evaluated with Cox models. Individual-level associations between SE and OS were estimated with an iterative multiple imputation approach and joint survival models. The population included 5294 patients (63 years median age). Median OS in immunotherapy group was 16.4 months (95%CI [14.1–NR]) and was higher than in chemotherapy group (11.6 months; 95%CI [11.0–12.2]). Improved OS was observed for the immunotherapy group after 3 months for subjects with performance status 0–1 (HR = 0.59; 95%CI [0.42–0.83], p < 0.01). The associations between rwPFS and TNT with OS were close (
τ
=0.57). Results emphasized a survival improvement with immunotherapy for patients in good health condition. There was moderate evidence of individual-level association between candidate SE and OS. |
|---|---|
| AbstractList | Treatment of metastatic non-small cell lung cancer (mNSCLC) has been modified due to the development of immunotherapy. We assessed survival outcomes (overall [OS] and progression-free [rwPFS] survivals, time-to-next-treatment [TNT]) in mNSCLC patients after first-line immunotherapy and chemotherapy in real-life settings. Association between rwPFS and TNT, two candidate surrogate endpoints (SE), with OS was assessed. This retrospective multi-center study uses data from patients included in the Epidemio-Strategy Medico-Economic program with mNSCLC over 2015–2019. The impact of treatment on rwPFS/OS was evaluated with Cox models. Individual-level associations between SE and OS were estimated with an iterative multiple imputation approach and joint survival models. The population included 5294 patients (63 years median age). Median OS in immunotherapy group was 16.4 months (95%CI [14.1–NR]) and was higher than in chemotherapy group (11.6 months; 95%CI [11.0–12.2]). Improved OS was observed for the immunotherapy group after 3 months for subjects with performance status 0–1 (HR = 0.59; 95%CI [0.42–0.83], p < 0.01). The associations between rwPFS and TNT with OS were close (
$$\uptau$$
τ
=0.57). Results emphasized a survival improvement with immunotherapy for patients in good health condition. There was moderate evidence of individual-level association between candidate SE and OS. Treatment of metastatic non-small cell lung cancer (mNSCLC) has been modified due to the development of immunotherapy. We assessed survival outcomes (overall [OS] and progression-free [rwPFS] survivals, time-to-next-treatment [TNT]) in mNSCLC patients after first-line immunotherapy and chemotherapy in real-life settings. Association between rwPFS and TNT, two candidate surrogate endpoints (SE), with OS was assessed. This retrospective multi-center study uses data from patients included in the Epidemio-Strategy Medico-Economic program with mNSCLC over 2015-2019. The impact of treatment on rwPFS/OS was evaluated with Cox models. Individual-level associations between SE and OS were estimated with an iterative multiple imputation approach and joint survival models. The population included 5294 patients (63 years median age). Median OS in immunotherapy group was 16.4 months (95%CI [14.1-NR]) and was higher than in chemotherapy group (11.6 months; 95%CI [11.0-12.2]). Improved OS was observed for the immunotherapy group after 3 months for subjects with performance status 0-1 (HR = 0.59; 95%CI [0.42-0.83], p < 0.01). The associations between rwPFS and TNT with OS were close ([Formula: see text]=0.57). Results emphasized a survival improvement with immunotherapy for patients in good health condition. There was moderate evidence of individual-level association between candidate SE and OS. Treatment of metastatic non-small cell lung cancer (mNSCLC) has been modified due to the development of immunotherapy. We assessed survival outcomes (overall [OS] and progression-free [rwPFS] survivals, time-to-next-treatment [TNT]) in mNSCLC patients after first-line immunotherapy and chemotherapy in real-life settings. Association between rwPFS and TNT, two candidate surrogate endpoints (SE), with OS was assessed. This retrospective multi-center study uses data from patients included in the Epidemio-Strategy Medico-Economic program with mNSCLC over 2015–2019. The impact of treatment on rwPFS/OS was evaluated with Cox models. Individual-level associations between SE and OS were estimated with an iterative multiple imputation approach and joint survival models. The population included 5294 patients (63 years median age). Median OS in immunotherapy group was 16.4 months (95%CI [14.1–NR]) and was higher than in chemotherapy group (11.6 months; 95%CI [11.0–12.2]). Improved OS was observed for the immunotherapy group after 3 months for subjects with performance status 0–1 (HR = 0.59; 95%CI [0.42–0.83], p < 0.01). The associations between rwPFS and TNT with OS were close (τ=0.57). Results emphasized a survival improvement with immunotherapy for patients in good health condition. There was moderate evidence of individual-level association between candidate SE and OS. Treatment of metastatic non-small cell lung cancer (mNSCLC) has been modified due to the development of immunotherapy. We assessed survival outcomes (overall [OS] and progression-free [rwPFS] survivals, time-to-next-treatment [TNT]) in mNSCLC patients after first-line immunotherapy and chemotherapy in real-life settings. Association between rwPFS and TNT, two candidate surrogate endpoints (SE), with OS was assessed. This retrospective multi-center study uses data from patients included in the Epidemio-Strategy Medico-Economic program with mNSCLC over 2015–2019. The impact of treatment on rwPFS/OS was evaluated with Cox models. Individual-level associations between SE and OS were estimated with an iterative multiple imputation approach and joint survival models. The population included 5294 patients (63 years median age). Median OS in immunotherapy group was 16.4 months (95%CI [14.1–NR]) and was higher than in chemotherapy group (11.6 months; 95%CI [11.0–12.2]). Improved OS was observed for the immunotherapy group after 3 months for subjects with performance status 0–1 (HR = 0.59; 95%CI [0.42–0.83], p < 0.01). The associations between rwPFS and TNT with OS were close ( τ =0.57). Results emphasized a survival improvement with immunotherapy for patients in good health condition. There was moderate evidence of individual-level association between candidate SE and OS. Abstract Treatment of metastatic non-small cell lung cancer (mNSCLC) has been modified due to the development of immunotherapy. We assessed survival outcomes (overall [OS] and progression-free [rwPFS] survivals, time-to-next-treatment [TNT]) in mNSCLC patients after first-line immunotherapy and chemotherapy in real-life settings. Association between rwPFS and TNT, two candidate surrogate endpoints (SE), with OS was assessed. This retrospective multi-center study uses data from patients included in the Epidemio-Strategy Medico-Economic program with mNSCLC over 2015–2019. The impact of treatment on rwPFS/OS was evaluated with Cox models. Individual-level associations between SE and OS were estimated with an iterative multiple imputation approach and joint survival models. The population included 5294 patients (63 years median age). Median OS in immunotherapy group was 16.4 months (95%CI [14.1–NR]) and was higher than in chemotherapy group (11.6 months; 95%CI [11.0–12.2]). Improved OS was observed for the immunotherapy group after 3 months for subjects with performance status 0–1 (HR = 0.59; 95%CI [0.42–0.83], p < 0.01). The associations between rwPFS and TNT with OS were close ( $$\uptau$$ τ =0.57). Results emphasized a survival improvement with immunotherapy for patients in good health condition. There was moderate evidence of individual-level association between candidate SE and OS. Treatment of metastatic non-small cell lung cancer (mNSCLC) has been modified due to the development of immunotherapy. We assessed survival outcomes (overall [OS] and progression-free [rwPFS] survivals, time-to-next-treatment [TNT]) in mNSCLC patients after first-line immunotherapy and chemotherapy in real-life settings. Association between rwPFS and TNT, two candidate surrogate endpoints (SE), with OS was assessed. This retrospective multi-center study uses data from patients included in the Epidemio-Strategy Medico-Economic program with mNSCLC over 2015–2019. The impact of treatment on rwPFS/OS was evaluated with Cox models. Individual-level associations between SE and OS were estimated with an iterative multiple imputation approach and joint survival models. The population included 5294 patients (63 years median age). Median OS in immunotherapy group was 16.4 months (95%CI [14.1–NR]) and was higher than in chemotherapy group (11.6 months; 95%CI [11.0–12.2]). Improved OS was observed for the immunotherapy group after 3 months for subjects with performance status 0–1 (HR = 0.59; 95%CI [0.42–0.83], p < 0.01). The associations between rwPFS and TNT with OS were close ( $$\uptau$$ τ=0.57). Results emphasized a survival improvement with immunotherapy for patients in good health condition. There was moderate evidence of individual-level association between candidate SE and OS. Treatment of metastatic non-small cell lung cancer (mNSCLC) has been modified due to the development of immunotherapy. We assessed survival outcomes (overall [OS] and progression-free [rwPFS] survivals, time-to-next-treatment [TNT]) in mNSCLC patients after first-line immunotherapy and chemotherapy in real-life settings. Association between rwPFS and TNT, two candidate surrogate endpoints (SE), with OS was assessed. This retrospective multi-center study uses data from patients included in the Epidemio-Strategy Medico-Economic program with mNSCLC over 2015-2019. The impact of treatment on rwPFS/OS was evaluated with Cox models. Individual-level associations between SE and OS were estimated with an iterative multiple imputation approach and joint survival models. The population included 5294 patients (63 years median age). Median OS in immunotherapy group was 16.4 months (95%CI [14.1-NR]) and was higher than in chemotherapy group (11.6 months; 95%CI [11.0-12.2]). Improved OS was observed for the immunotherapy group after 3 months for subjects with performance status 0-1 (HR = 0.59; 95%CI [0.42-0.83], p < 0.01). The associations between rwPFS and TNT with OS were close ([Formula: see text]=0.57). Results emphasized a survival improvement with immunotherapy for patients in good health condition. There was moderate evidence of individual-level association between candidate SE and OS.Treatment of metastatic non-small cell lung cancer (mNSCLC) has been modified due to the development of immunotherapy. We assessed survival outcomes (overall [OS] and progression-free [rwPFS] survivals, time-to-next-treatment [TNT]) in mNSCLC patients after first-line immunotherapy and chemotherapy in real-life settings. Association between rwPFS and TNT, two candidate surrogate endpoints (SE), with OS was assessed. This retrospective multi-center study uses data from patients included in the Epidemio-Strategy Medico-Economic program with mNSCLC over 2015-2019. The impact of treatment on rwPFS/OS was evaluated with Cox models. Individual-level associations between SE and OS were estimated with an iterative multiple imputation approach and joint survival models. The population included 5294 patients (63 years median age). Median OS in immunotherapy group was 16.4 months (95%CI [14.1-NR]) and was higher than in chemotherapy group (11.6 months; 95%CI [11.0-12.2]). Improved OS was observed for the immunotherapy group after 3 months for subjects with performance status 0-1 (HR = 0.59; 95%CI [0.42-0.83], p < 0.01). The associations between rwPFS and TNT with OS were close ([Formula: see text]=0.57). Results emphasized a survival improvement with immunotherapy for patients in good health condition. There was moderate evidence of individual-level association between candidate SE and OS. |
| ArticleNumber | 9584 |
| Author | Debieuvre, Didier Filleron, Thomas Belaroussi, Yaniss Bellera, Carine Pasquier, David Martin, Anne-Laure Girard, Nicolas Perol, Maurice Schott, Roland Mathoulin-Pélissier, Simone Cousin, Sophie Bouteiller, Fanny |
| Author_xml | – sequence: 1 givenname: Yaniss surname: Belaroussi fullname: Belaroussi, Yaniss email: yanissbelaroussi@gmail.com organization: UMR 1219, Univ. Bordeaux, Bordeaux Population Health Research Center, Epicene Team, Inserm CIC1401, Clinical and Epidemiological Research Unit, Institut Bergonié, Comprehensive Cancer Center – sequence: 2 givenname: Fanny surname: Bouteiller fullname: Bouteiller, Fanny organization: Inserm CIC1401, Clinical and Epidemiological Research Unit, Institut Bergonié, Comprehensive Cancer Center – sequence: 3 givenname: Carine surname: Bellera fullname: Bellera, Carine organization: UMR 1219, Univ. Bordeaux, Bordeaux Population Health Research Center, Epicene Team, Inserm CIC1401, Clinical and Epidemiological Research Unit, Institut Bergonié, Comprehensive Cancer Center – sequence: 4 givenname: David surname: Pasquier fullname: Pasquier, David organization: Radiotherapy Department, Centre Oscar Lambret – sequence: 5 givenname: Maurice surname: Perol fullname: Perol, Maurice organization: Medical Oncology Department, Centre Léon Bérard – sequence: 6 givenname: Didier surname: Debieuvre fullname: Debieuvre, Didier organization: Chest Disease Department, GHRMSA – sequence: 7 givenname: Thomas surname: Filleron fullname: Filleron, Thomas organization: Biostatistic and Health Data Science Unit, Institut Claudius Régaud IUTC-O – sequence: 8 givenname: Nicolas surname: Girard fullname: Girard, Nicolas organization: Medical Oncology Department, Institut du Thorax Curie-Montsouris – sequence: 9 givenname: Roland surname: Schott fullname: Schott, Roland organization: Medical Oncology Department, Institut de Cancérologie Strasbourg Europe – sequence: 10 givenname: Simone surname: Mathoulin-Pélissier fullname: Mathoulin-Pélissier, Simone organization: UMR 1219, Univ. Bordeaux, Bordeaux Population Health Research Center, Epicene Team, Inserm CIC1401, Clinical and Epidemiological Research Unit, Institut Bergonié, Comprehensive Cancer Center – sequence: 11 givenname: Anne-Laure surname: Martin fullname: Martin, Anne-Laure organization: Health Data and Partnership Department, Unicancer – sequence: 12 givenname: Sophie surname: Cousin fullname: Cousin, Sophie organization: Early Phase Trials Unit, Department of Medical Oncology, Institut Bergonié, Comprehensive Cancer Center |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/37311845$$D View this record in MEDLINE/PubMed https://hal.science/hal-04228653$$DView record in HAL |
| BookMark | eNp9Uk1v1DAUjFARLaV_gAOyxAUOAX_EjnNCVQW00kocgLPlOM-7XiXxYjtb9Yfwf3E2bWl7aA6OPZmZ954zr4uj0Y9QFG8J_kQwk59jRXgjS0xZyYTIK3lRnFBc8ZIySo8e7I-Lsxi3OD-cNhVpXhXHrGaEyIqfFH9_TmHv9rpHfkrGDxCRt2ink4MxRXTt0gYNkHRMGTIoN1HGQfc9MpCXfhrXyOjRQEABDLi9m4ENDD5tIOjdDfIBuWGYxntAR2RdiKns3QjIjUhnqe7z0QKKkFK2eFO8tLqPcHb7Pi1-f_v66-KyXP34fnVxvioNr3kqW95gzVpeUyuxxaa2FgtiBGMthUpwyWVFW85wVXMKvGrAGCxsJ-rMB27ZaXG1-HZeb9UuuEGHG-W1UwfAh7XSIc_dg-qaFkPFa2CtqAQmUoLoiCWARWcxa7PXl8VrN7UDdCbfX9D9I9PHX0a3UWu_VwRTUTFOs8PHxWHzRHd5vlIzhitKpeBsTzL3w2214P9MEJMaXJz_iR7BT1FRSbkkGNcz9f0T6tZPYcz3emDxppEUZ9a7h-3f17-LSibIhWCCjzGAVcbNofDzNK7PY6g5mGoJpsrBVIdgqrkD-kR65_6siC2imMnjGsL_tp9R_QM7dvZ4 |
| CitedBy_id | crossref_primary_10_1038_s41591_024_03352_5 crossref_primary_10_1001_jamanetworkopen_2024_4278 crossref_primary_10_3390_curroncol32040206 crossref_primary_10_3390_ijms26136348 crossref_primary_10_1007_s12274_023_6342_2 crossref_primary_10_1007_s11864_024_01270_9 crossref_primary_10_1016_j_jare_2024_07_036 crossref_primary_10_1002_cam4_70007 crossref_primary_10_3390_biomedicines12081792 crossref_primary_10_1016_j_jpainsymman_2024_07_008 crossref_primary_10_3390_cancers17121932 |
| Cites_doi | 10.1038/s41598-019-40748-7 10.1371/journal.pone.0135673 10.21037/tlcr-21-15 10.1080/00273171.2011.568786 10.1056/NEJMoa1606774 10.1002/cpt.1658 10.1200/JCO.2017.35.15_suppl.TPS9101 10.1634/theoncologist.2018-0307 10.1200/JCO.2018.36.18_suppl.LBA9000 10.1016/S1470-2045(17)30690-3 10.1016/0197-2456(96)00075-X 10.1093/annonc/mds226 10.1097/EDE.0b013e3181a819a1 10.1002/sim.5874 10.2217/imt-2019-0177 10.1016/j.cllc.2021.02.001 10.1002/sim.8162 10.1007/s10637-019-00843-y 10.1007/s00262-020-02613-9 10.1016/j.lungcan.2019.05.005 10.1002/cam4.2806 10.1056/NEJMoa1810865 10.1016/j.cllc.2020.09.017 10.1016/S0140-6736(18)32409-7 10.2217/fon-2019-0348 10.1002/cncr.32383 10.1007/s00262-012-1270-0 10.1056/NEJMoa1716948 10.1186/s12885-015-2027-x 10.1186/s12916-017-0831-7 10.1016/j.jtho.2016.05.021 10.1016/j.critrevonc.2017.11.014 10.1002/sim.7084 10.1056/NEJMoa1801005 |
| ContentType | Journal Article |
| Copyright | The Author(s) 2023 2023. The Author(s). The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. Attribution |
| Copyright_xml | – notice: The Author(s) 2023 – notice: 2023. The Author(s). – notice: The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: Attribution |
| DBID | C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7X7 7XB 88A 88E 88I 8FE 8FH 8FI 8FJ 8FK ABUWG AEUYN AFKRA AZQEC BBNVY BENPR BHPHI CCPQU DWQXO FYUFA GHDGH GNUQQ HCIFZ K9. LK8 M0S M1P M2P M7P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI Q9U 7X8 1XC VOOES 5PM DOA |
| DOI | 10.1038/s41598-023-36623-1 |
| DatabaseName | Springer Nature OA Free Journals CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Health & Medical Collection (Proquest) ProQuest Central (purchase pre-March 2016) Biology Database (Alumni Edition) Medical Database (Alumni Edition) Science Database (Alumni Edition) ProQuest SciTech Collection ProQuest Natural Science Journals Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) One Sustainability ProQuest Central ProQuest Central Essentials Biological Science Collection ProQuest Central Natural Science Collection ProQuest One Community College ProQuest Central Proquest Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Biological Sciences ProQuest Health & Medical Collection Medical Database Science Database Biological Science Database (ProQuest) ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) One Applied & Life Sciences ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central Basic MEDLINE - Academic Hyper Article en Ligne (HAL) Hyper Article en Ligne (HAL) (Open Access) PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Biology Journals (Alumni Edition) ProQuest Central ProQuest One Applied & Life Sciences ProQuest One Sustainability ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Science Journals (Alumni Edition) ProQuest Biological Science Collection ProQuest Central Basic ProQuest Science Journals ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | CrossRef Publicly Available Content Database MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: PIMPY name: Publicly Available Content Database url: http://search.proquest.com/publiccontent sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Biology |
| EISSN | 2045-2322 |
| EndPage | 11 |
| ExternalDocumentID | oai_doaj_org_article_d9b0e457e3b6460188e6d1f1e06df03b PMC10264352 oai:HAL:hal-04228653v1 37311845 10_1038_s41598_023_36623_1 |
| Genre | Research Support, Non-U.S. Gov't Multicenter Study Journal Article |
| GroupedDBID | 0R~ 3V. 4.4 53G 5VS 7X7 88A 88E 88I 8FE 8FH 8FI 8FJ AAFWJ AAJSJ AAKDD ABDBF ABUWG ACGFS ACSMW ACUHS ADBBV ADRAZ AENEX AEUYN AFKRA AJTQC ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS AZQEC BAWUL BBNVY BCNDV BENPR BHPHI BPHCQ BVXVI C6C CCPQU DIK DWQXO EBD EBLON EBS ESX FYUFA GNUQQ GROUPED_DOAJ GX1 HCIFZ HH5 HMCUK HYE KQ8 LK8 M0L M1P M2P M48 M7P M~E NAO OK1 PIMPY PQQKQ PROAC PSQYO RNT RNTTT RPM SNYQT UKHRP AASML AAYXX AFFHD AFPKN CITATION PHGZM PHGZT PJZUB PPXIY PQGLB CGR CUY CVF ECM EIF NPM 7XB 8FK K9. PKEHL PQEST PQUKI Q9U 7X8 1XC VOOES 5PM |
| ID | FETCH-LOGICAL-c575t-b590a3b572f80f0c7ff061c633b2e46585842b5304752e549ecc06fd67f80e5f3 |
| IEDL.DBID | DOA |
| ISICitedReferencesCount | 15 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=001011884700025&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 2045-2322 |
| IngestDate | Tue Oct 14 19:05:19 EDT 2025 Tue Nov 04 02:06:48 EST 2025 Tue Oct 14 20:17:39 EDT 2025 Sun Nov 09 10:09:17 EST 2025 Tue Oct 07 08:55:13 EDT 2025 Thu Jan 02 22:52:42 EST 2025 Sat Nov 29 06:34:14 EST 2025 Tue Nov 18 21:08:20 EST 2025 Fri Feb 21 02:37:18 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Carcinoma Time-to-Treatment Immunotherapy Humans Non-Small-Cell Lung Patients Lung Neoplasms |
| Language | English |
| License | 2023. The Author(s). Attribution: http://creativecommons.org/licenses/by Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c575t-b590a3b572f80f0c7ff061c633b2e46585842b5304752e549ecc06fd67f80e5f3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| ORCID | 0000-0003-0724-0659 0000-0002-3296-423X |
| OpenAccessLink | https://doaj.org/article/d9b0e457e3b6460188e6d1f1e06df03b |
| PMID | 37311845 |
| PQID | 2825599820 |
| PQPubID | 2041939 |
| PageCount | 11 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_d9b0e457e3b6460188e6d1f1e06df03b pubmedcentral_primary_oai_pubmedcentral_nih_gov_10264352 hal_primary_oai_HAL_hal_04228653v1 proquest_miscellaneous_2825810071 proquest_journals_2825599820 pubmed_primary_37311845 crossref_citationtrail_10_1038_s41598_023_36623_1 crossref_primary_10_1038_s41598_023_36623_1 springer_journals_10_1038_s41598_023_36623_1 |
| PublicationCentury | 2000 |
| PublicationDate | 2023-06-13 |
| PublicationDateYYYYMMDD | 2023-06-13 |
| PublicationDate_xml | – month: 06 year: 2023 text: 2023-06-13 day: 13 |
| PublicationDecade | 2020 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London – name: England |
| PublicationTitle | Scientific reports |
| PublicationTitleAbbrev | Sci Rep |
| PublicationTitleAlternate | Sci Rep |
| PublicationYear | 2023 |
| Publisher | Nature Publishing Group UK Nature Publishing Group Nature Portfolio |
| Publisher_xml | – name: Nature Publishing Group UK – name: Nature Publishing Group – name: Nature Portfolio |
| References | Chen, Parikh, Abouzaid, Purnomo, McGuiness, Hussein (CR17) 2017; 23 Mok, Wu, Kudaba, Kowalski, Cho, Turna (CR4) 2019; 393 Reck, Rodríguez-Abreu, Robinson, Hui, Csőszi, Fülöp (CR2) 2016; 375 Ksienski, Wai, Croteau, Freeman, Chan, Fiorino (CR35) 2019; 133 Brahmer, Rodríguez-Abreu, Robinson, Hui, Csőszi, Fülöp (CR3) 2017; 18 Paz-Ares, Luft, Vicente, Tafreshi, Gümüş, Mazières (CR10) 2018; 379 Facchinetti, Di Maio, Perrone, Tiseo (CR38) 2021; 10 Austin (CR23) 2011; 46 Gandhi, Rodríguez-Abreu, Gadgeel, Esteban, Felip, De Angelis (CR8) 2018; 378 Velcheti, Chandwani, Chen, Pietanza, Piperdi, Burke (CR36) 2019; 11 CR11 Schisterman, Cole, Platt (CR22) 2009; 20 Jotte, Cappuzzo, Vynnychenko, Stroyakovskiy, Rodriguez Abreu, Hussein (CR9) 2018; 36 Khozin, Carson, Zhi, Tucker, Lee, Light (CR31) 2019; 24 Cortellini, Tiseo, Banna, Cappuzzo, Aerts, Barbieri (CR37) 2020; 69 Simeone, Nordstrom, Patel, Klein (CR1) 2019; 15 Austin (CR24) 2016; 35 Savina, Gourgou, Italiano, Dinart, Rondeau, Penel (CR19) 2018; 123 Tamiya, Tamiya, Hosoya, Taniguchi, Yokoyama, Fukuda (CR34) 2019; 37 Chudley, McCann, Mander, Tjelle, Campos-Perez, Godeseth (CR18) 2012; 61 Khozin, Miksad, Adami, Boyd, Brown, Gossai (CR12) 2019; 125 Teng, Wang, Chen, Lin, Hwang (CR15) 2015; 10 Liang, Li, Fraser, Ko, Corzo, Enger (CR16) 2015; 15 Schemper, Kaider, Wakounig, Heinze (CR25) 2013; 32 Mountzios, de Toma, Economopoulou, Friedlaender, Banini, Lo Russo (CR40) 2021; 22 Cheng, Cramb, Baade, Youlden, Nwogu, Reid (CR29) 2016; 11 Savina, Le Cesne, Blay, Ray-Coquard, Mir, Toulmonde (CR14) 2017; 15 CR28 Amrane, Geier, Corre, Léna, Léveiller, Gadby (CR32) 2020; 9 CR27 Textor, van der Zander, Gilthorpe, Liskiewicz, Ellison (CR21) 2016; 45 Song, Zhang, Shang, Zhang (CR33) 2019; 9 Schemper, Smith (CR20) 1996; 17 Frost, Kollmeier, Misch, Vollbrecht, Grah, Matthes (CR39) 2021; 22 Peters, Adjei, Gridelli, Reck, Kerr, Felip (CR5) 2012; 23 Beaulieu-Jones, Finlayson, Yuan, Altman, Kohane, Prasad (CR30) 2020; 107 Socinski, Jotte, Cappuzzo, Orlandi, Stroyakovskiy, Nogami (CR7) 2018; 378 West, Nishio, Dols, Saito, Howland, Hoang (CR6) 2017; 35 Pilz, Manegold, Schmid-Bindert (CR13) 2012; 1 Sofeu, Emura, Rondeau (CR26) 2019; 38 RM Jotte (36623_CR9) 2018; 36 P Song (36623_CR33) 2019; 9 36623_CR28 M Reck (36623_CR2) 2016; 375 JR Brahmer (36623_CR3) 2017; 18 MA Socinski (36623_CR7) 2018; 378 M Schemper (36623_CR20) 1996; 17 K Amrane (36623_CR32) 2020; 9 M Tamiya (36623_CR34) 2019; 37 HJ West (36623_CR6) 2017; 35 36623_CR11 T-YD Cheng (36623_CR29) 2016; 11 BK Beaulieu-Jones (36623_CR30) 2020; 107 D Ksienski (36623_CR35) 2019; 133 LR Pilz (36623_CR13) 2012; 1 G Mountzios (36623_CR40) 2021; 22 V Velcheti (36623_CR36) 2019; 11 TSK Mok (36623_CR4) 2019; 393 N Frost (36623_CR39) 2021; 22 S Khozin (36623_CR12) 2019; 125 PC Austin (36623_CR23) 2011; 46 L Paz-Ares (36623_CR10) 2018; 379 CL Sofeu (36623_CR26) 2019; 38 C-C Chen (36623_CR17) 2017; 23 A Cortellini (36623_CR37) 2020; 69 C Liang (36623_CR16) 2015; 15 EF Schisterman (36623_CR22) 2009; 20 L Chudley (36623_CR18) 2012; 61 S Khozin (36623_CR31) 2019; 24 S Peters (36623_CR5) 2012; 23 M Savina (36623_CR14) 2017; 15 36623_CR27 JC Simeone (36623_CR1) 2019; 15 M Savina (36623_CR19) 2018; 123 C-LJ Teng (36623_CR15) 2015; 10 M Schemper (36623_CR25) 2013; 32 F Facchinetti (36623_CR38) 2021; 10 L Gandhi (36623_CR8) 2018; 378 J Textor (36623_CR21) 2016; 45 PC Austin (36623_CR24) 2016; 35 |
| References_xml | – volume: 9 start-page: 4278 issue: 1 year: 2019 ident: CR33 article-title: Real-world evidence and clinical observations of the treatment of advanced non-small cell lung cancer with PD-1/PD-L1 inhibitors publication-title: Sci. Rep. doi: 10.1038/s41598-019-40748-7 – volume: 10 start-page: e0135673 issue: 8 year: 2015 ident: CR15 article-title: Optimal sequence of irinotecan and oxaliplatin-based regimens in metastatic colorectal cancer: A population-based observational study publication-title: PloS One doi: 10.1371/journal.pone.0135673 – volume: 10 start-page: 2917 issue: 6 year: 2021 end-page: 2936 ident: CR38 article-title: First-line immunotherapy in non-small cell lung cancer patients with poor performance status: A systematic review and meta-analysis publication-title: Transl. Lung Cancer Res. doi: 10.21037/tlcr-21-15 – volume: 46 start-page: 399 issue: 3 year: 2011 end-page: 424 ident: CR23 article-title: An introduction to propensity score methods for reducing the effects of confounding in observational studies publication-title: Multivar. Behav. Res. doi: 10.1080/00273171.2011.568786 – volume: 375 start-page: 1823 issue: 19 year: 2016 end-page: 33 ident: CR2 article-title: Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1606774 – volume: 107 start-page: 843 issue: 4 year: 2020 end-page: 852 ident: CR30 article-title: Examining the use of real-world evidence in the regulatory process publication-title: Clin. Pharmacol. Ther. doi: 10.1002/cpt.1658 – volume: 35 start-page: TPS9101 issue: 15 year: 2017 end-page: TPS9101 ident: CR6 article-title: IMpower132: A phase III clinical program—1L atezolizumab plus platinum-based chemotherapy in chemo-naive advanced non-squamous NSCLC publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2017.35.15_suppl.TPS9101 – volume: 24 start-page: 648 issue: 5 year: 2019 end-page: 56 ident: CR31 article-title: Real-world outcomes of patients with metastatic non-small cell lung cancer treated with programmed cell death protein 1 inhibitors in the year following U.S. regulatory approval publication-title: Oncologist doi: 10.1634/theoncologist.2018-0307 – volume: 36 start-page: LBA9000 issue: 18_suppl year: 2018 end-page: LBA9000 ident: CR9 article-title: IMpower131: Primary PFS and safety analysis of a randomized phase III study of atezolizumab + carboplatin + paclitaxel or nab-paclitaxel vs carboplatin + nab-paclitaxel as 1L therapy in advanced squamous NSCLC publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2018.36.18_suppl.LBA9000 – volume: 18 start-page: 1600 issue: 12 year: 2017 end-page: 1609 ident: CR3 article-title: Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): A multicentre, international, randomised, open-label phase 3 trial publication-title: Lancet Oncol. doi: 10.1016/S1470-2045(17)30690-3 – volume: 17 start-page: 343 issue: 4 year: 1996 end-page: 346 ident: CR20 article-title: A note on quantifying follow-up in studies of failure time publication-title: Control. Clin. Trials doi: 10.1016/0197-2456(96)00075-X – volume: 23 start-page: vii56 issue: 7 year: 2012 end-page: 64 ident: CR5 article-title: Metastatic non-small-cell lung cancer (NSCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up publication-title: Ann. Oncol. doi: 10.1093/annonc/mds226 – volume: 23 start-page: 236 issue: 2 year: 2017 end-page: 246 ident: CR17 article-title: Real-world treatment patterns, time to next treatment, and economic outcomes in relapsed or refractory multiple myeloma patients treated with pomalidomide or Carfilzomib publication-title: J. Manag. Care Spec. Pharm. – volume: 20 start-page: 488 issue: 4 year: 2009 end-page: 495 ident: CR22 article-title: Overadjustment bias and unnecessary adjustment in epidemiologic studies publication-title: Epidemiol. Camb. Mass doi: 10.1097/EDE.0b013e3181a819a1 – volume: 32 start-page: 4781 issue: 27 year: 2013 end-page: 90 ident: CR25 article-title: Estimating the correlation of bivariate failure times under censoring publication-title: Stat. Med. doi: 10.1002/sim.5874 – volume: 11 start-page: 1541 issue: 18 year: 2019 end-page: 1554 ident: CR36 article-title: Outcomes of first-line pembrolizumab monotherapy for PD-L1-positive (TPS ≥50%) metastatic NSCLC at US oncology practices publication-title: Immunotherapy doi: 10.2217/imt-2019-0177 – volume: 22 start-page: 411 issue: 5 year: 2021 end-page: 422 ident: CR39 article-title: Pembrolizumab as first-line palliative therapy in PD-L1 overexpressing (≥ 50%) NSCLC: Real-world results with special focus on PS ≥ 2, brain metastases, and steroids publication-title: Clin. Lung Cancer doi: 10.1016/j.cllc.2021.02.001 – volume: 38 start-page: 2928 issue: 16 year: 2019 end-page: 42 ident: CR26 article-title: One-step validation method for surrogate endpoints using data from multiple randomized cancer clinical trials with failure-time endpoints publication-title: Stat. Med. doi: 10.1002/sim.8162 – volume: 37 start-page: 1266 issue: 6 year: 2019 end-page: 1273 ident: CR34 article-title: Efficacy and safety of pembrolizumab as first-line therapy in advanced non-small cell lung cancer with at least 50% PD-L1 positivity: A multicenter retrospective cohort study (HOPE-001) publication-title: Investig. New Drugs doi: 10.1007/s10637-019-00843-y – volume: 1 start-page: 26 issue: 1 year: 2012 end-page: 35 ident: CR13 article-title: Statistical considerations and endpoints for clinical lung cancer studies: Can progression free survival (PFS) substitute overall survival (OS) as a valid endpoint in clinical trials for advanced non-small-cell lung cancer? publication-title: Transl. Lung Cancer Res. – volume: 69 start-page: 2209 issue: 11 year: 2020 end-page: 21 ident: CR37 article-title: Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50% publication-title: Cancer Immunol. Immunother. doi: 10.1007/s00262-020-02613-9 – volume: 133 start-page: 110 year: 2019 end-page: 6 ident: CR35 article-title: Pembrolizumab for advanced nonsmall cell lung cancer: Efficacy and safety in everyday clinical practice publication-title: Lung Cancer doi: 10.1016/j.lungcan.2019.05.005 – ident: CR27 – volume: 9 start-page: 2309 issue: 7 year: 2020 end-page: 2316 ident: CR32 article-title: First-line pembrolizumab for non-small cell lung cancer patients with PD-L1 ≥50% in a multicenter real-life cohort: The PEMBREIZH study publication-title: Cancer Med. doi: 10.1002/cam4.2806 – volume: 379 start-page: 2040 issue: 21 year: 2018 end-page: 51 ident: CR10 article-title: Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1810865 – volume: 22 start-page: e180 issue: 2 year: 2021 end-page: e192 ident: CR40 article-title: Steroid use independently predicts for poor outcomes in patients with advanced NSCLC and high PD-L1 expression receiving first-line pembrolizumab monotherapy publication-title: Clin. Lung Cancer doi: 10.1016/j.cllc.2020.09.017 – volume: 393 start-page: 1819 issue: 10183 year: 2019 end-page: 30 ident: CR4 article-title: Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): A randomised, open-label, controlled, phase 3 trial publication-title: Lancet Lond. Engl. doi: 10.1016/S0140-6736(18)32409-7 – volume: 15 start-page: 3491 issue: 30 year: 2019 end-page: 3502 ident: CR1 article-title: Treatment patterns and overall survival in metastatic non-small-cell lung cancer in a real-world US setting publication-title: Fut. Oncol. Lond. Engl. doi: 10.2217/fon-2019-0348 – volume: 125 start-page: 4019 issue: 22 year: 2019 end-page: 32 ident: CR12 article-title: Real-world progression, treatment, and survival outcomes during rapid adoption of immunotherapy for advanced non-small cell lung cancer publication-title: Cancer doi: 10.1002/cncr.32383 – volume: 61 start-page: 2161 issue: 11 year: 2012 end-page: 2170 ident: CR18 article-title: DNA fusion-gene vaccination in patients with prostate cancer induces high-frequency CD8(+) T-cell responses and increases PSA doubling time publication-title: Cancer Immunol. Immunother. CII doi: 10.1007/s00262-012-1270-0 – volume: 378 start-page: 2288 issue: 24 year: 2018 end-page: 301 ident: CR7 article-title: Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1716948 – volume: 15 start-page: 1019 year: 2015 ident: CR16 article-title: The treatment patterns, efficacy, and safety of nab (®)-paclitaxel for the treatment of metastatic breast cancer in the United States: Results from health insurance claims analysis publication-title: BMC Cancer doi: 10.1186/s12885-015-2027-x – ident: CR11 – volume: 15 start-page: 78 issue: 1 year: 2017 ident: CR14 article-title: Patterns of care and outcomes of patients with METAstatic soft tissue SARComa in a real-life setting: The METASARC observational study publication-title: BMC Med. doi: 10.1186/s12916-017-0831-7 – volume: 11 start-page: 1653 issue: 10 year: 2016 end-page: 71 ident: CR29 article-title: The international epidemiology of lung cancer: Latest trends, disparities, and tumor characteristics publication-title: J. Thorac. Oncol. doi: 10.1016/j.jtho.2016.05.021 – volume: 123 start-page: 21 year: 2018 end-page: 41 ident: CR19 article-title: Meta-analyses evaluating surrogate endpoints for overall survival in cancer randomized trials: A critical review publication-title: Crit. Rev. Oncol. Hematol. doi: 10.1016/j.critrevonc.2017.11.014 – volume: 45 start-page: 1887 issue: 6 year: 2016 end-page: 94 ident: CR21 article-title: Robust causal inference using directed acyclic graphs: The R package “dagitty” publication-title: Int. J. Epidemiol. – volume: 35 start-page: 5642 issue: 30 year: 2016 end-page: 55 ident: CR24 article-title: Variance estimation when using inverse probability of treatment weighting (IPTW) with survival analysis publication-title: Stat. Med. doi: 10.1002/sim.7084 – volume: 378 start-page: 2078 issue: 22 year: 2018 end-page: 92 ident: CR8 article-title: Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1801005 – ident: CR28 – volume: 15 start-page: 3491 issue: 30 year: 2019 ident: 36623_CR1 publication-title: Fut. Oncol. Lond. Engl. doi: 10.2217/fon-2019-0348 – volume: 36 start-page: LBA9000 issue: 18_suppl year: 2018 ident: 36623_CR9 publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2018.36.18_suppl.LBA9000 – ident: 36623_CR11 – volume: 125 start-page: 4019 issue: 22 year: 2019 ident: 36623_CR12 publication-title: Cancer doi: 10.1002/cncr.32383 – volume: 22 start-page: e180 issue: 2 year: 2021 ident: 36623_CR40 publication-title: Clin. Lung Cancer doi: 10.1016/j.cllc.2020.09.017 – volume: 378 start-page: 2288 issue: 24 year: 2018 ident: 36623_CR7 publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1716948 – volume: 37 start-page: 1266 issue: 6 year: 2019 ident: 36623_CR34 publication-title: Investig. New Drugs doi: 10.1007/s10637-019-00843-y – ident: 36623_CR28 – volume: 1 start-page: 26 issue: 1 year: 2012 ident: 36623_CR13 publication-title: Transl. Lung Cancer Res. – volume: 23 start-page: vii56 issue: 7 year: 2012 ident: 36623_CR5 publication-title: Ann. Oncol. doi: 10.1093/annonc/mds226 – volume: 46 start-page: 399 issue: 3 year: 2011 ident: 36623_CR23 publication-title: Multivar. Behav. Res. doi: 10.1080/00273171.2011.568786 – volume: 375 start-page: 1823 issue: 19 year: 2016 ident: 36623_CR2 publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1606774 – volume: 61 start-page: 2161 issue: 11 year: 2012 ident: 36623_CR18 publication-title: Cancer Immunol. Immunother. CII doi: 10.1007/s00262-012-1270-0 – volume: 11 start-page: 1541 issue: 18 year: 2019 ident: 36623_CR36 publication-title: Immunotherapy doi: 10.2217/imt-2019-0177 – volume: 18 start-page: 1600 issue: 12 year: 2017 ident: 36623_CR3 publication-title: Lancet Oncol. doi: 10.1016/S1470-2045(17)30690-3 – volume: 32 start-page: 4781 issue: 27 year: 2013 ident: 36623_CR25 publication-title: Stat. Med. doi: 10.1002/sim.5874 – volume: 22 start-page: 411 issue: 5 year: 2021 ident: 36623_CR39 publication-title: Clin. Lung Cancer doi: 10.1016/j.cllc.2021.02.001 – volume: 15 start-page: 78 issue: 1 year: 2017 ident: 36623_CR14 publication-title: BMC Med. doi: 10.1186/s12916-017-0831-7 – volume: 23 start-page: 236 issue: 2 year: 2017 ident: 36623_CR17 publication-title: J. Manag. Care Spec. Pharm. – volume: 107 start-page: 843 issue: 4 year: 2020 ident: 36623_CR30 publication-title: Clin. Pharmacol. Ther. doi: 10.1002/cpt.1658 – volume: 133 start-page: 110 year: 2019 ident: 36623_CR35 publication-title: Lung Cancer doi: 10.1016/j.lungcan.2019.05.005 – volume: 393 start-page: 1819 issue: 10183 year: 2019 ident: 36623_CR4 publication-title: Lancet Lond. Engl. doi: 10.1016/S0140-6736(18)32409-7 – volume: 24 start-page: 648 issue: 5 year: 2019 ident: 36623_CR31 publication-title: Oncologist doi: 10.1634/theoncologist.2018-0307 – volume: 38 start-page: 2928 issue: 16 year: 2019 ident: 36623_CR26 publication-title: Stat. Med. doi: 10.1002/sim.8162 – volume: 15 start-page: 1019 year: 2015 ident: 36623_CR16 publication-title: BMC Cancer doi: 10.1186/s12885-015-2027-x – volume: 17 start-page: 343 issue: 4 year: 1996 ident: 36623_CR20 publication-title: Control. Clin. Trials doi: 10.1016/0197-2456(96)00075-X – volume: 35 start-page: 5642 issue: 30 year: 2016 ident: 36623_CR24 publication-title: Stat. Med. doi: 10.1002/sim.7084 – volume: 69 start-page: 2209 issue: 11 year: 2020 ident: 36623_CR37 publication-title: Cancer Immunol. Immunother. doi: 10.1007/s00262-020-02613-9 – ident: 36623_CR27 – volume: 378 start-page: 2078 issue: 22 year: 2018 ident: 36623_CR8 publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1801005 – volume: 45 start-page: 1887 issue: 6 year: 2016 ident: 36623_CR21 publication-title: Int. J. Epidemiol. – volume: 20 start-page: 488 issue: 4 year: 2009 ident: 36623_CR22 publication-title: Epidemiol. Camb. Mass doi: 10.1097/EDE.0b013e3181a819a1 – volume: 9 start-page: 2309 issue: 7 year: 2020 ident: 36623_CR32 publication-title: Cancer Med. doi: 10.1002/cam4.2806 – volume: 379 start-page: 2040 issue: 21 year: 2018 ident: 36623_CR10 publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1810865 – volume: 10 start-page: 2917 issue: 6 year: 2021 ident: 36623_CR38 publication-title: Transl. Lung Cancer Res. doi: 10.21037/tlcr-21-15 – volume: 11 start-page: 1653 issue: 10 year: 2016 ident: 36623_CR29 publication-title: J. Thorac. Oncol. doi: 10.1016/j.jtho.2016.05.021 – volume: 9 start-page: 4278 issue: 1 year: 2019 ident: 36623_CR33 publication-title: Sci. Rep. doi: 10.1038/s41598-019-40748-7 – volume: 10 start-page: e0135673 issue: 8 year: 2015 ident: 36623_CR15 publication-title: PloS One doi: 10.1371/journal.pone.0135673 – volume: 123 start-page: 21 year: 2018 ident: 36623_CR19 publication-title: Crit. Rev. Oncol. Hematol. doi: 10.1016/j.critrevonc.2017.11.014 – volume: 35 start-page: TPS9101 issue: 15 year: 2017 ident: 36623_CR6 publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2017.35.15_suppl.TPS9101 |
| SSID | ssj0000529419 |
| Score | 2.469054 |
| Snippet | Treatment of metastatic non-small cell lung cancer (mNSCLC) has been modified due to the development of immunotherapy. We assessed survival outcomes (overall... Abstract Treatment of metastatic non-small cell lung cancer (mNSCLC) has been modified due to the development of immunotherapy. We assessed survival outcomes... |
| SourceID | doaj pubmedcentral hal proquest pubmed crossref springer |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 9584 |
| SubjectTerms | 631/67 631/67/1612 631/67/1612/1350 Carcinoma, Non-Small-Cell Lung - drug therapy Chemotherapy Humanities and Social Sciences Humans Immunotherapy Life Sciences Lung cancer Lung Neoplasms - drug therapy Metastases Metastasis multidisciplinary Non-small cell lung carcinoma Patients Santé publique et épidémiologie Science Science (multidisciplinary) Small cell lung carcinoma Survival Time-to-Treatment |
| SummonAdditionalLinks | – databaseName: Biological Science Database (ProQuest) dbid: M7P link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwELaggMSFNzRQkEHcIGoSx459QgVR9VBVlXioN8tObBppN2k3u5X6Q_i_zDjeVEtFLxzj2E6cfJ4Zz5OQ91lZKysam9YKVTeF5KlCL4vGSiMFM2rUQ_48rI6O5MmJOo4KtyG6Va5pYiDUTV-jjnwXYyw5nA2K7NPZeYpVo9C6Gkto3CZ3MEsCC657x5OOBa1YZa5irEzG5O4A_ApjygqWMgGcP803-FFI2w9c5hSdIq9LnNcdJ_-yngamtP_wf5fziDyI4ijdG_HzmNxy3RNybyxQefmU_P62AlICYKT9agkTu4H2nsZcrANFJS6du6XBsKS2pl3fpcPczGYU7QF0BoSE1girBQXC6lpUXlBAyTyGfV3SfkFbjFCZGsxAfQsSaYriL207amComcGld3RwwUv7Gfmx__X7l4M0FnJIa5AGl6nlKjPM8qrwMvNZXXkPYkQtGLOFK0EGAimosBwtgLxwcGIFXGXCN6KC_o579pxswQrcNqHW-obbEsY6IDdGmKaUhZNCMVWqqjEJyde_U9cxyzkW25jpYG1nUo8Q0AABHSCg84R8mMacjTk-buz9GVEy9cT83KGhX_zScbvrRtnMlbxyzIoSzrxSOtHkPneZaHzGbELeAcY25jjYO9TYFpKyCc4u4Ek7a-zoSFkGfQWchLydbgNNwB9rOtevxj4S3V9gihcjYqdHsYrBmbLkCZEbWN54l807XXsa8o6DLAryKy8S8nEN-6v3-vcHe3nzMl6R-wXuR6wHxXbI1nKxcq_J3fpi2Q6LN2FD_wH2h1Mc priority: 102 providerName: ProQuest |
| Title | Survival outcomes of patients with metastatic non-small cell lung cancer receiving chemotherapy or immunotherapy as first-line in a real-life setting |
| URI | https://link.springer.com/article/10.1038/s41598-023-36623-1 https://www.ncbi.nlm.nih.gov/pubmed/37311845 https://www.proquest.com/docview/2825599820 https://www.proquest.com/docview/2825810071 https://hal.science/hal-04228653 https://pubmed.ncbi.nlm.nih.gov/PMC10264352 https://doaj.org/article/d9b0e457e3b6460188e6d1f1e06df03b |
| Volume | 13 |
| WOSCitedRecordID | wos001011884700025&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 2045-2322 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000529419 issn: 2045-2322 databaseCode: DOA dateStart: 20110101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources (ISSN International Center) customDbUrl: eissn: 2045-2322 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000529419 issn: 2045-2322 databaseCode: M~E dateStart: 20110101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVPQU databaseName: Biological Science Database (ProQuest) customDbUrl: eissn: 2045-2322 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000529419 issn: 2045-2322 databaseCode: M7P dateStart: 20110101 isFulltext: true titleUrlDefault: http://search.proquest.com/biologicalscijournals providerName: ProQuest – providerCode: PRVPQU databaseName: Health & Medical Collection (Proquest) customDbUrl: eissn: 2045-2322 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000529419 issn: 2045-2322 databaseCode: 7X7 dateStart: 20110101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 2045-2322 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000529419 issn: 2045-2322 databaseCode: BENPR dateStart: 20110101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Publicly Available Content Database customDbUrl: eissn: 2045-2322 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000529419 issn: 2045-2322 databaseCode: PIMPY dateStart: 20110101 isFulltext: true titleUrlDefault: http://search.proquest.com/publiccontent providerName: ProQuest – providerCode: PRVPQU databaseName: Science Database customDbUrl: eissn: 2045-2322 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000529419 issn: 2045-2322 databaseCode: M2P dateStart: 20110101 isFulltext: true titleUrlDefault: https://search.proquest.com/sciencejournals providerName: ProQuest |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3db9MwELdgA4kXxOcIjMog3iBaYseO_bihTUPaqoovlSfLTmwtUpqipp20P4T_l7skLSsT8MKLpTp24vp-vg_77kzImyQrtJOliwuNWzdMiVijl0XplFWSW93vQ349y8djNZ3qybWrvtAnrE8P3E_cQald4jORe-5kBtaDUl6WaUh9IsuQcIfcF7Sea8ZUn9Wb6SzVQ5RMwtVBC5IKo8kYj7kEmR-nW5KoS9gP8uUC3SFv6po3XSZ_OzftxNHJA3J_0CPpYT_-h-SWbx6Ru_3NklePyY9PK-ABgCI6Xy0BVL6l80CHJKotxd1XOvNLi_FEVUGbeRO3M1vXFDfyaQ0cgBaIhwUFjugr3HWgQN7ZEK91RecLWmFoyabCtjRUoErGqLfSqqEWutoafgZPW9-5Vz8hX06OP78_jYcbGOIC1Lhl7IROLHciZ0ElISnyEED-F5Jzx3wGyguoL8wJPLoTzIOpCYBIZChlDu29CPwp2YF_4J8R6lwohcugrwc-YaUtM8W8kprrTOeljUi6poYphvTkeEtGbbpjcq5MT0EDFDQdBU0akbebPt_75Bx_bX2ERN60xMTaXQXAzQxwM_-CW0ReA0S23nF6eGawrsumJgW_hC_trxFkBpbQGgwSFmDcsiQirzaPYTEjYW3j56u-jUK_FXjFXg-4zad4zsEYzERE1BYUt8ay_aSpLrqE4aBEguIpWETerVH7a1x_nrDn_2PCXpB7DBcdXvfE98nOcrHyL8md4nJZtYsRuZ1P865UI7J7dDyefBx1KxnKczbBModyd_LhfPLtJ9SuS_8 |
| linkProvider | Directory of Open Access Journals |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1R3JbtQw1CoFBBf2ZaCAQXCCqImdOM4BobJUU3UYVaJUvRk7sWmkmaRMZormQ_gNvpH3slVDRW89cIxjO7bzdr-FkJd-mCZGZMZLEzTdMBl5CXpZZEZqKbhOGjvkwSgej-XhYbK3Rn53sTDoVtnRxJpQZ2WKNvJNjLGMQDdg_rvjHx5WjcLb1a6ERgMWu3b5E1S26u3OR_i_rxjb_rT_Yei1VQW8FESTuWeixNfcRDFz0nd-GjsHPC0VnBtmQ2DIwJKZifA6KmIW1CfYpC9cJmLobyPHYd5L5DKIEUzWroJ7vU0Hb83CIGljc3wuNyvgjxjDxrjHBUgaXrDC_-oyAcDVjtAJ86yEe9ZR86_b2poJbt_8347vFrnRitt0q8GP22TNFnfI1aYA5_Iu-fVlAaQSkI2WizlsxFa0dLTNNVtRNFLTqZ1rDLvKU1qUhVdN9WRC8b6DToBQ0hTRZkaBcdgcjTMUsGDahrUtaTmjOUbg9A26oi4HidtD8Z7mBdUwVE_g0Vla2doL_R75eiFncp-sww7sQ0KNcVlkQhhrgZxqobNQMitFwpMwiTM9IEEHPipts7hjMZGJqr0JuFQNyCkAOVWDnAoG5HU_5rjJYXJu7_cIlX1PzD9eN5Sz76olZypLjG_DKLbciBB0eimtyAIXWF9kzudmQF4ATK_MMdwaKWyrk86JiJ_AlzY6WFUt5azUKaAOyPP-NdA8_LG6sOWi6SPRvQemeNBgSP8pHnPQmcNoQOQK7qysZfVNkR_VedVB1gb5PGID8qZDs9N1_fvAHp2_jWfk2nD_80iNdsa7j8l1hrQAa1_xDbI-ny3sE3IlPZnn1expTUwo-XbR6PcH1CauPA |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1R3JbtQw1CplERf2JVDAIDhBNBk7dpwDQoVStepoNBKLegt2YtNIM0mZzBTNh_AzfB3vZauGit564BjHdmzn7X4LIS-DMI2NzIyfxmi6YUr4MXpZZEZpJbmOGzvk11E0HqvDw3iyQX53sTDoVtnRxJpQZ2WKNvIBxlgK0A1YMHCtW8RkZ_fd8Q8fK0jhTWtXTqMBkQO7-gnqW_V2fwf-9SvGdj9-_rDntxUG_BTElIVvRBxobkTEnApckEbOAX9LJeeG2RCYM7BnZgReTQlmQZWCDQfSZTKC_lY4DvNeIpcjTFpeuw1OevsO3qCFw7iN0wm4GlTAKzGejXGfS5A6_OEaL6xLBgCHO0KHzLPS7lmnzb9ubmuGuHvzfz7KW-RGK4bT7QZvbpMNW9whV5vCnKu75NenJZBQQEJaLhewKVvR0tE2B21F0XhNZ3ahMRwrT2lRFn4109MpxXsQOgUCSlNEpzkFhmJzNNpQwI5ZG-62ouWc5hiZ0zfoirocJHEfxX6aF1TDUD2FR2dpZWvv9Hvky4WcyX2yCTuwDwk1xmXChDDWApnVUmehYlbJmMdhHGXaI8MOlJK0ze6ORUamSe1lwFXSgF8C4JfU4JcMPfK6H3Pc5DY5t_d7hNC-J-YlrxvK-fekJXNJFpvAhiKy3MgQdH2lrMyGbmgDmbmAG4-8APhem2Nve5RgW52MTgp-Al_a6uA2aSlqlZwCrUee96-BFuKP1YUtl00fhW4_MMWDBlv6T_GIgy4dCo-oNTxaW8v6myI_qvOtgwwOcrtgHnnTodzpuv59YI_O38Yzcg2wLhntjw8ek-sMyQKWxOJbZHMxX9on5Ep6ssir-dOarlDy7aKx7w9Pabb5 |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Survival+outcomes+of+patients+with+metastatic+non-small+cell+lung+cancer+receiving+chemotherapy+or+immunotherapy+as+first-line+in+a+real-life+setting&rft.jtitle=Scientific+reports&rft.au=Belaroussi%2C+Yaniss&rft.au=Bouteiller%2C+Fanny&rft.au=Bellera%2C+Carine&rft.au=Pasquier%2C+David&rft.date=2023-06-13&rft.issn=2045-2322&rft.eissn=2045-2322&rft.volume=13&rft.issue=1&rft_id=info:doi/10.1038%2Fs41598-023-36623-1&rft.externalDBID=n%2Fa&rft.externalDocID=10_1038_s41598_023_36623_1 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2045-2322&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2045-2322&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2045-2322&client=summon |